|
1. Biologie
|
|
|
|
|
2. Etiologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
Mini-tumours' created to battle cancer [BBC News]
|
|
|
|
|
|
"This
has been a huge issue in the past, when people were using mouse models
it was taking six to eight months to get to the results. "With this tool
we can get results in a couple of months and I think we can get even
faster."
|
|
|
|
|
|
|
Lab-grown ‘mini tumours’ could personalise cancer treatment [Cancer Research UK]
|
|
|
|
|
|
Researchers
treated the lab-grown ‘mini tumours’ with a range of drugs. They then
looked to see how this compared to how successful treatment was in those
patients. The approach found a drug that had a chance of shrinking a
patient’s tumour in almost 9 in 10 cases. Drugs that didn't work in
patients also had no effect on the mini tumours.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
Cost of Trials [In the Pipeline]
|
|
|
|
|
|
If
cost-of-trials is indeed increasing, as it seems to be, then it would
follow that we might want to be pickier about what we put into those
trials. But that’s not what’s happening.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
Deal-hungry Takeda forges another R&D alliance [FierceBiotech]
|
|
|
|
|
|
The
link-up with Fred Hutchinson Cancer Research Center and the University
of Washington—dubbed The Seattle Partnership for Research on Innovative
Therapies, or SPRInT—is aimed at taking “promising biological targets
associated with disease to the next step to develop candidate drugs into
potential treatments for patients,” says the Japanese drugmaker.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
NICE sticks with ‘no’ for earlier use of Halaven [PharmaTimes]
|
|
|
|
|
|
In
a Final Appraisal Determination, the National Institute for Health and
Care Excellence said Halaven (eribulin) was too expensive for use in
patients locally advanced or secondary breast cancer in adults who have
had only one chemotherapy regimen.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
Trump: New HHS chief has already lowered drug prices [STAT]
|
|
|
|
|
|
None
of those policies has moved forward in the week since the announcement,
either regulatorily or legislatively. The only other major action HHS
has taken during Azar’s short tenure is also still in the proposal
stage, and it focuses on short-term health insurance plans, not drugs.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Q&A: Blazing trails through the Wild West of research metrics [Nature]
|
|
|
|
|
|
If
you’re trying to ascertain impact, you can find hundreds of answers
based on different indicators and data sources. From a data point of
view, an organization such as Google could change that. Unfortunately,
they give away their search tools but keep all of the data, so we don’t
have open, collective, standardized tools yet.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
Science needs to redefine excellence [Nature]
|
|
|
|
|
|
What
does excellence mean? How is it measured? When do we know that we have
reached the required standard? These are difficult questions, but if the
excellence agenda is to be taken seriously, they must be asked — even
if they cannot be adequately answered.
|
|
|
|
|
|